anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: This study aimed to compare the effectiveness of liver resection (LR) and microwave ablation (MWA) in hepatocellular carcinoma (HCC) patients with early recurrence and varying stages of cirrhosis.
METHOD: This study analyzed patients with HCC who underwent hepatectomy and experienced early tumor recurrence (≤3 cm) between December 2002 and December 2020 at the Tongji Hospital. Treatment effectiveness was assessed using a propensity score matching (PSM) analysis.
RESULTS: This study included 295 patients (106, LR; 189, MWA), 86 patients in each of the 2 groups were chosen for further comparison, after PSM. After PSM, both LR and MWA demonstrated similar recurrence-free survival (RFS) and overall survival (OS) rates (p = 0.060 and p = 0.118, respectively). However, the LR group had more treatment-related complications. In patients with moderate or severe cirrhosis, no significant differences in RFS or OS rates were found between the LR and MWA groups (p = 0.779 and p = 0.772, respectively). In patients without cirrhosis or with mild cirrhosis, LR showed better RFS and OS rates than MWA (p = 0.024 and p = 0.047, respectively). Multivariate analysis after PSM identified moderate or severe cirrhosis and recurrence intervals ≤12 months as independent predictors of poor RFS and OS in patients with early recurrence of HCC.
CONCLUSION: LR is more effective than MWA for early recurrence of HCC in patients without cirrhosis or with mild cirrhosis, showing improved RFS and OS rates. In patients with moderate or severe cirrhosis, the OS and RFS were statistically equal between the two therapies. However, MWA may be preferred owing to its low complication rate.
Although obstructive sleep apnea (OSA) is associated with impaired glucose tolerance and diabetes, it remains unclear whether OSA treatment with continuous positive airway pressure (CPAP) has metabolic benefits. To determine the effect of 8-hour nightly CPAP treatment on glucose metabolism in individuals with prediabetes and OSA. In a randomized, controlled parallel group study, 39 participants were randomized (2:1) to receive either 8-hour nightly CPAP (n=26) or oral placebo (n=13). Sleep was polysomnographically recorded in the laboratory on each night. CPAP adherence was ensured by continuous supervision. Participants continued their daily daytime routine activities outside the laboratory. Glucose metabolism was assessed at baseline and after 2-weeks of assigned treatment using both the oral and intravenous glucose tolerance tests (OGTT and ivGTT, respectively). The primary outcome was the overall glucose response as quantified by the area under the curve for glucose during 2-hour oral glucose tolerance testing.
BACKGROUND: Hyperprogressive disease (HPD) can be described as an accelerated increase in the growth rate of tumors combined with rapid clinical deterioration observed in a subset of cancer patients undergoing immunotherapy, specifically with immune checkpoint inhibitors (ICIs). The reported incidence of HPD ranges from 5.9% to 43.1% in patients receiving ICIs. In this context, identifying reliable predictive risk factors for HPD is crucial as it may allow for earlier intervention and ultimately improve patient outcomes.
METHODS: This study retrospectively analyzed ten metastatic renal cell carcinoma (mRCC) patients. The identification of HPD was based on the diagnostic criteria proposed by Ferrara R et al. This study aimed to investigate whether there is an association between LN size and HPD using a cutoff value of 3 cm for LN size. Given the limited sample size, Fisher's exact test was used to test this association. We conducted a Kaplan-Meier (KM) analysis to estimate the median overall survival (OS) of patients with HPD and compared it to those without HPD.
RESULTS: Three patients (30%) developed HPD, while seven (70%) did not. Fisher's exact test revealed a statistically significant association between the HPD and LN size ≥ 3 cm (p=0.008). In the HPD group, the median OS was significantly shorter, with a median OS of 3 months, whereas in the non-HPD group, the median OS was not reached (P =0.001).
CONCLUSION: The present study found a significant association between LN size ≥ 3 cm in the pretreatment period and HPD development.
<P>PROBLEM TO BE SOLVED: To provide new compositions and methods for obtaining concentrated preparations of factor IX and furthermore, a formulation for the factor IX suitable for storage and administration.  <P>SOLUTION: The compositions are freezed or freeze-dried and contain the factor IX, an extender such as glycine and a refrigeration protectant. The concentration range of the factor IX is preferably about 0.1 to at least 20 mg/ml (equivalent to about 20 to at least 4,000 U/ml). The preferable extender contains glycine and/or a salt of magnesium, calcium or a chloride and preferably is in the concentration range of about 0.5 to 300 mM. The suitable refrigeration protectant contains a polyol such as mannitol and sucrose and preferably is in the concentration range of about 0.5 to 2%.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The present disclosure provides a film for application to the living body, which contains a regenerated cellulose and is advantageous for reducing the time required for attachment of regenerated cellulose to living tissues. A film (10) for application to the living body according to the present disclosure contains a regenerated cellulose and an accelerator. The accelerator accelerates attachment of the regenerated cellulose to living tissues. This film (10) for application to the living body is self-supporting, and has a thickness of from 20 nm to 5,000 nm. The accelerator is represented by formula (A). In the formula, each of a and c represents an integer of 0 or more; each of b and d represents an integer of 1 or more; R1 represents a hydrogen atom, an acyl group or an alkyl group; and R2 represents a hydrogen atom, a hydroxyl group, an acyl group or an alkyl group.
According to the present invention, specific Lactobacillus sp. strains, Bifidobacterium sp. strains, Streptococcus sp. strains, or Collinsella sp. strains are isolated from human feces, are highly safe, and have various physiological activities such as immune regulatory effects, immune enhancing effects, anti-allergic effects, anti-inflammatory effects, colitis alleviation effects, arthritis alleviating effects, anti-obesity effects, anti-stress effects, anti-anxiety effects, anti-depression effects, or anti-schizophrenia effects. The specific Lactobacillus sp. strain, the specific Bifidobacterium sp. strain, the specific Streptococcus sp. strain or the specific Collinsella sp. strain according to the present invention can be used as a substance for immune regulation, immune enhancement, inflammatory response inhibition, and stress alleviation or as a functional food and pharmaceutical substance useful for preventing, alleviating, and treating allergic diseases, inflammatory diseases, colitis, arthritis, obesity, anxiety disorders, depression, schizophrenia or the like.
Phenylephrine 500ug will be added to the first litre of ringer's lactate infused on initiation of spinal anaesthesia. If the phenylephrine infusion protocol is being used, and the mean arterial pressure (MAP) rises to greater than 20% of the initial MAP, and where this rise in MAP is not due to a recent bolus of either phenylephrine or ephedrine (within 2 minutes), the Ringers Lactate infusion will be switched off. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to gynecology, and concerns treating bacterial vaginosis. That is ensured by administration of a herbal tincture containing camomile flowers, pine buds, birch buds, celandine herb, bird cherry, oak bark and alder collective fruits at the equal ratio, dosed 250.0 ml once a day. Additionally, sterile tissues wetted in said tincture are introduced intravaginally. The therapeutic course is 20 days. ^ EFFECT: method provides integrated effect on vaginal dysbiosis and hormonal rebalancing. ^ 1 tbl, 1 ex
PURPOSE: A heparin-conjugated polyethylenimine is provided to ensure low cytotoxin, high blood compatibility and high transfection efficiency in a serum medium and in-vivo, and to be used as non-virus with excellent safety. CONSTITUTION: A polyethyleneimine is conjugated with heparin. The molecular weight of a heparin moiety in the heparin-conjugated polyethylenimine is 100-100,000. The gene delivery comprises polyethyleneimine to which heparin is bonded. The gene delivery complex has a delivery gene bonded with the gene delivery. The delivery gene includes pDNA or siRNA(small interfering RNA).
PURPOSE:To provide a new compound having inhibitory activity against cholesterol acyl transferase-acyl coenzyme A, thus useful for curing or preventing diseases due to cholesterol accumulation such as hyperlipemia. CONSTITUTION:The compound of the formula (R1-R4 are each H or acyl), which can be obtained by the following process: a productive strain for the new compound, belonging to Aspergillus (e.g. Aspergillus sp. FO-1289, FERM P-121194), is cultured in a medium by e.g. shaking or aerobic culture under aerobic conditions, followed by extraction with e.g. a solvent and then purification and separation. The compound, FO-1289 substance has the following physicochemical characteristics: neutral yellow powder, solubility: soluble to methanol, ethanol, acetonitrile, ethyl acetate, benzene; insoluble to water. A cholesterol is converted into a cholesterol ester by acyl group rearrangement by the action of acyl coenzyme A, and this ester is accumulated in the cells and blood lipoproteins. The enzyme catalyzing this rearrangement reaction is cholesterol acyl transferase acyl CoA, and the compound of the formula inhibits this enzyme system.
Participants who are randomised to the intervention arm will complete all three modules of the EMBody intervention across six weeks. They will also complete online surveys at baseline (T0), weeks two (T1), four (T2), six (T3), 10 (T4), and 18 (T5). Data will be analysed after the T5 data collection point. There will be an additional 12-month long-term follow up (T6), with a go/no-go decision depending on trial findings; these data will be published separately.
This is a Phase 2, single-arm, open-label (all knew the intervention of study), and multicenter (when more than 1 hospital or medical school team work on a medical research study) study to explore the efficacy, safety and pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of ibrutinib in Japanese participants with relapsed (the return of a medical problem) or refractory (not responding to treatment) MCL. The study will consist of a Screening Phase of 30 days prior to first dose of study drug followed by treatment Phase and a post-treatment follow-up Phase. Participants will receive ibrutinib 560 milligram (mg) orally, once daily on a 28-day cycle until disease progression (or relapse if the participant achieved a CR), unacceptable toxicity, or study end, whichever occurs first. Treatment Phase will have disease assessments every 8 weeks up to 24 weeks after start of study drug, then every 12 weeks thereafter to assess efficacy up to 2 years after last participant enrolled. Efficacy will primarily be evaluated by ORR. Participants' safety will be monitored throughout the study.
Participants in this arm are randomized to a 3-week baseline period with repeated weekly assessment after the initial intake. Following the 3-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy - Integrated (WET-I) followed by a 4-week follow-up phase with repeated weekly assessments.
The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
114,190. Imray, 0., (Soc. of Chemical In. dustry in Basle). March 20, 1917. Medicinal preparations.-An opium preparation soluble in water and containing the various alkaloids in their natural proportions, is obtained by first extracting the opium with water, and then treating the residue, which contains narcotine, papaverine, and thebaine, with dilute alcohol containing a small proportion of formic acid; the alcoholic solution is evaporated to remove alcohol and free acid, filtered, and mixed with the aqueous extract; the mixed solution is diluted if necessary, filtered, and evaporated to dryness in vacuo; any albuminous matter may be removed from the filtered solution by means of a lead salt followed by sulphuretted hydrogen, prior to the final evaporation.
Patients referred to conventional PR or eligible for PR but declined or cannot access. Using a standardized script at the randomization phone call, study staff will deliver verbal instructions to slowly and steadily increase one's walking and exercise each week. Participants will be asked to perform exercise of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover. Use of the Borg rating scale for dyspnea will be reviewed with each participant. Exercise is defined as planned PA, outside of activities performed as part of one's daily routine. Exercise can be walking in the community or using exercise equipment at a local gym. Adapted written materials reinforce the verbal instructions. Participants will receive this 45-page spiral-bound book with information about aerobic and strength training exercises.
Poor response to Bacillus Calmette-Guérin (BCG) immunotherapy remains a major barrier in the management of patients with non-muscle invasive bladder cancer (NMIBC). Multiple factors are associated with poor outcomes, including biological aging and female sex. More recently, it has emerged that a B-cell-infiltrated pretreatment immune microenvironment of NMIBC tumors can influence the response to intravesically administered BCG. The mechanisms underlying the roles of B cells in NMIBC are poorly understood. Here, we show that B-cell-dominant tertiary lymphoid structures (TLSs), a hallmark feature of the chronic mucosal immune response, are abundant and located close to the epithelial compartment in pretreatment tumors from BCG non-responders. Digital spatial proteomic profiling of whole tumor sections from male and female patients with NMIBC who underwent treatment with intravesical BCG, revealed higher expression of immune exhaustion-associated proteins within the tumor-adjacent TLSs in both responders and non-responders. Chronic local inflammation, induced by the N-butyl-N-(4-hydroxybutyl) nitrosamine carcinogen, led to TLS formation with recruitment and differentiation of the immunosuppressive atypical B-cell (ABC) subset within the bladder microenvironment, predominantly in aging female mice compared to their male counterparts. Depletion of ABCs simultaneous to BCG treatment delayed cancer progression in female mice. Our findings provide evidence indicating a role for ABCs in BCG response and will inform future development of therapies targeting the B-cell-exhaustion axis.
Alcohol abuse is associated with several diseases, such as hepatocellular carcinoma, cirrhosis, and extrahepatic malignancies. Recently, we reported albumin platelet product (APP) and modified APP (mAPP) as novel indices of liver fibrosis staging and prognosis in patients without alcoholic liver diseases. This retrospective cohort study aimed to extend application of APP and mAPP in prognosis prediction of patients with alcoholic liver diseases. We enrolled 222 patients with alcoholic liver diseases based on their medical records. Cut-off values of APP = 4.349 and mAPP = 2.484 were adopted based on a past report. Hazard ratios of APP and mAPP were compared to those of albumin-bilirubin score and fibrosis-4 index. The primary and secondary endpoints were carcinogenesis and death, respectively. Thus, APP = 4.349 and mAPP = 2.484 significantly differentiated cancer-free survival and overall survival in univariate analysis. Hazard ratios of mAPP = 2.484 were greater than those of the albumin-bilirubin score of -2.270 and fibrosis-4 index of 3.25. Multivariate analysis revealed mAPP = 2.484 as an independent risk factor for carcinogenesis and overall death. In conclusion, mAPP is a simple index to stratify patient's risk for carcinogenesis and death.
680,788. Medicines. GENERAL ANILINE & FILM CORPORATION. May 8, 1951 [May 19, 1950], No. 10792/51. Class 81 (i). A medicine comprises a mixture of a normally pyrogenic pharmaceutical product selected from the group consisting of vaccines, polysaccharide and emulsified fats, and a pre-determined amount of a polyvinyl pyrolidone sufficient to minimize substantially the normal pyrogenic effect of the pharmaceutical product. The vaccines specified are those of typhoid, diphtheria, smallpox, whooping cough and common cold. The polysaccharide sold under the name glucouronic acid is mentioned. U.S.A. Specification 2,265,450 is referred to.
In 2023, published research on COVID-19 remains prominent. The aim of this article is to highlight important developments in infectious disease evidence unrelated to COVID-19 that were published in 2023. The literature was screened for sound new evidence relevant to internal medicine specialists and subspecialists whose focus of practice is not infectious diseases. The highlighted publications relate to various organisms and patient populations. One article provides insight into the updated guidelines for the diagnosis and management of infective endocarditis. Several articles address the management of sepsis and bacteremia: comparison of cefepime versus piperacillin-tazobactam, ceftobiprole for the treatment of complicated Staphylococcus aureus bacteremia, and early switch from intravenous to oral antibiotics in patients with gram-negative bacteremia. Another article examines differences in all-cause mortality in patients with Clostridioides difficile infection who receive different treatments. Additional articles provide evidence about the treatment of patients with HIV infection: the utility of preexposure prophylaxis to prevent HIV infection, the efficacy of pitavastatin in reducing cardiovascular disease, and the efficacy of dexamethasone for the treatment of tuberculous meningitis in persons with HIV.
Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
BACKGROUND: The incidence of anterior cruciate ligament (ACL) injuries in children is on the rise. Despite this trend, the optimal management of these injuries remains a matter of ongoing debate. In this light, our study seeks to assess the clinical, radiological, and functional outcomes of transphyseal ACL reconstruction in preadolescent patients in the medium-term.
METHODS: This prospective study included preadolescent patients aged up to 12 years who underwent ACL transphyseal reconstruction between 2010 and 2020 and had a minimum follow-up of 2 years. Clinical assessments encompassed joint stability and range of motion. Furthermore, leg length discrepancy (LLD) and femorotibial alignment were evaluated both clinically and radiologically using full-length lower limb standing radiographs. Pre- and postoperative functional outcomes were assessed using the International Knee Documentation Committee (IKDC) and Lysholm scales, and the return to normal sports activity was evaluated using the ACL-Return to Sport after Injury (ACL-RSI) scale. Complications and relevant follow-up data were also recorded. Statistical analyses were conducted to evaluate these outcomes.
RESULTS: A total of 35 preadolescent patients, consisting of 24 males and 11 females, with a mean age at surgery of 11.2 ± 0.7 years (8.7-12), were included in the study. The mean follow-up was 52.3 ± 20.7 months (24.1-95.9). No significant growth disturbances or clinically relevant LLD were evidenced. All patients demonstrated clinically stable knees with full range of motion at the 2-year follow-up. There were statistically significant improvements in pre- and postoperative IKDC (39.3 ± 13.5 vs. 99.7 ± 0.8, p < 0.005) and Lysholm scores (48.2 ± 15.1 vs. 99.6 ± 1.4, p < 0.005). All but two patients were able to return to their pre-injury level of sports activity, with a mean ACL-RSI score of 93.5 ± 1.3. The analysis revealed an 8.6% rerupture rate and an 11.4% rate of contralateral ACL injuries, with 5-year survival rates of 92.3% and 88.8%, respectively. Subgroup analyses based on age, gender, surgical delay, or associated meniscal lesions did not reveal any significant differences in functional outcomes. Additionally, there was no discernible relationship between age or timing of ACL reconstruction and the risk of meniscal injuries.
CONCLUSIONS: Our study reinforces the value of ACL reconstruction in skeletally immature preadolescent patients, with transphyseal technique proven to be a safe, effective, and technically simpler option, even for children under the age of 12. The findings indicate excellent functional outcomes, a high rate of successful return to sporting activities, and minimal to no incidence of growth-related complications in the medium-term.
LEVEL OF EVIDENCE: Level II, prospective comparative cohort study, before and after intervention.
Method and apparatus are disclosed for applying a therapeutic amount of a non-systemic vasoconstrictor inside the uterus to control abnormal uterine bleeding. The abnormal bleeding can be due to excessive menstrual blood flow, bleeding from a surgical procedure, postpartum bleeding or any other acute or chronic condition. The vasoconstrictor includes topical agents such as an alpha-adrenergic agonist, for example oxymetazoline. The delivery system can include a catheter having means for retaining position of a distal portion within the uterus. A proximal portion can extend outside of the body for coupling to a vasoconstrictor source, or alternatively, the proximal portion can terminate within the vaginal canal and include a docking port for coupling to a source of vasoconstrictor that is inserted therein. In other embodiments, an applicator is disclosed that is positioned in fluid communication with the lumen of the cervix and allows application of a vasoconstrictor therein.